DFV-890 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval

DFV-890 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

Jun 18, 2024 - 04:00

DFV-890 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

Read the original article

Tags:

Previous Article

MEDI-0618 by AstraZeneca for Migraine: Likelihood of Approval

Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer ...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Bright Health sells Medicare Advantage plans to Molina for $600 million

STAT+: Bright Health sells Medicare Advantage plans to ...

Jun 30, 2023

Surufatinib by Hutchison MediPharma for Neuroendocrine ...

Oct 25, 2023

AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

Dec 1, 2023